EFFECT OF SORAFENIB ON HUMAN COLON CANCER CELLS by Al Hassan, Marwa et al.
BAU Journal - Health and Wellbeing 
Volume 3 Issue 2 
ISSN: 2617-1635 Article 7 
April 2021 
EFFECT OF SORAFENIB ON HUMAN COLON CANCER CELLS 
Marwa Al Hassan 
PhD Student, Faculty of Science, Beirut Arab University, Debbieh, Lebanon, MHassan@bau.edu.lb 
Farah Reda 
PhD Student, Faculty of Science, Beirut Arab University, Debbieh, Lebanon, farahreda87@hotmail.com 
Ali Baltaji 
Student, Faculty of Medicine, Beirut Arab University, Beirut, Lebanon, aliibrahimbaltaji@gmail.com 
Julnar Usta 
Professor, Faculty of Medicine, American University of Beirut, Beirut, Lebanon, justa@aub.edu.lb 
Jamilah Borjac 
Professor, Faculty of Science, Beirut Arab University, Debbieh, Lebanon, j.borjac@bau.edu.lb 
Follow this and additional works at: https://digitalcommons.bau.edu.lb/hwbjournal 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Recommended Citation 
Al Hassan, Marwa; Reda, Farah; Baltaji, Ali; Usta, Julnar; and Borjac, Jamilah (2021) "EFFECT OF 
SORAFENIB ON HUMAN COLON CANCER CELLS," BAU Journal - Health and Wellbeing: Vol. 3 : Iss. 2 , Article 
7. 
Available at: https://digitalcommons.bau.edu.lb/hwbjournal/vol3/iss2/7 
This Article is brought to you for free and open access by Digital Commons @ BAU. It has been accepted for 
inclusion in BAU Journal - Health and Wellbeing by an authorized editor of Digital Commons @ BAU. For more 
information, please contact ibtihal@bau.edu.lb. 
EFFECT OF SORAFENIB ON HUMAN COLON CANCER CELLS 
Abstract 
ABSTRACT: Sorafenib, a kinase inhibitor, is among the approved drugs for the treatment of radioactive 
iodine resistant thyroid carcinoma, primary kidney and liver cancers. Reported targets of Sorafenib include 
VEGFR, Raf family, and PDGFR belonging to the general class of tyrosine kinases. Blocking growth signals 
in kidney and breast cancers underlie one of the mechanisms of Sorafenib antitumor effects’ leading to cell 
death. We hereby examine the effect of Sorafenib on human colon carcinoma cell-line HCT116. We also 
investigate the possible role of p53 in mediating this effect using mutant HCT116 p53-/- cells. Cultured 
wild and mutant cells are treated with Sorafenib (0-75µM) for 24 hr. This is followed by assessing the 
viability of cells using MTT and trypan blue exclusion assays. We also examined if Sorafenib mode of 
action is mediated by ROS. Levels of ROS were determined in the presence and absence of antioxidants 
using the colorimetric NBT assay. Our preliminary results show a concentration dependent decrease in 
viability (trypan blue) with an estimated EC50 of 10 and 25 µM for HCT116 and HCT116 p53-/- respectively. 
Compared to trypan blue, MTT results were similar in case of HCT116 p53-/- but were significantly different 
with HCT116. Furthermore we obtained a significant increase in level of ROS of: 37.11% and 31.30% 
for HCT116 and HCT116p53-/- respectively. However, 2 hours pre-incubation of cells with antioxidants, 
Trolox, N-acetylcysteine (NAC), and catalase, prior to Sorafenib treatment, exerted no different effect. No 
restoration of viability or decrease in generated ROS level was noted except when pre-incubated with NAC. 
Our preliminary findings show that Sorafenib action is independent of ROS level and p53 expression and 
further investigations on the mechanism(s) of Sorafenib action are ongoing. 
Keywords 
Sorafenib, Colon carcinoma, Apoptosis, ROS, Cell motility 
This article is available in BAU Journal - Health and Wellbeing: https://digitalcommons.bau.edu.lb/hwbjournal/vol3/
iss2/7 
1. INTRODUCTION 
Colorectal cancer, commonly known as bowel cancer, occurs in the colon, appendix, or 
rectum. CRC is the third most common cancer and known as the second most common cause of 
cancer death (Siegel, et al., 2020). From 2007 to 2016, incidence rates of colorectal cancer declined 
by 3.6% annually among adults 55 years of age and older, but increased by 2% annually among 
adults younger than age 55 (American Cancer Society, 2020). 
 
Diverse risk factors for colorectal cancer (CRC) include genetic predisposition and 
incidence of inflammatory bowel diseases (Andersen & Jess, 2013). Moreover, studies have 
associated coronary heart disease with an increased risk of CRC (Wang, et. al., 2019). In addition, 
many bacterial and viral agents were proposed among the risk factors for CRC (Macrae, 2020). 
Consistently, several distinct treatments and predictive measures are used to cure CRC 
(Iasonos, Chapman & Satagopan, 2016). Similar to different types of cancer, the treatment of colon 
cancer depends on its advancement stage. While surgery is generally curative at early stages; 
however when the cancer metastasizes, chemotherapeutic drugs are introduced in the treatment at 
later stages (Stein, Atanackovic, & Bokemeyer, 2011).  
Over the last five decades, many chemotherapeutic drugs were used, of which is 5-
fluorouracil (5-Fu), one of the most effective and most commonly used drugs to treat colorectal 
cancer. However, intrinsic and acquired resistance remains a main setback to its clinical efficacy 
(He et.al., 2017). 
Combined chemotherapeutic regimens are currently being adopted for the treatment of 
colorectal cancer such as oxaliplatin with 5-FU or leucovorin. This drug combination; FOLFOX, 
is currently considered as the first-line chemotherapy strategy for metastatic CRC (Jeught, et al., 
2018).  
In the recent years, novel chemotherapeutic and immunotherapeutic drugs have been 
developed and used in the treatment of colorectal cancer. Among the monoclonal antibodies used 
are panitumumab that targets epidermal growth factor receptors (EGFR) blocking cell division 
and growth (Ruthann, et al., 2007), and bevacizumab that inhibits the activity of VEGF and thus 
inhibiting thus angiogenesis. These drugs have been used in combination with 5-FU (Pavlidis, 
2013). 
Sorafenib (Figure 1 showing structure), a drug approved for the treatment of patients with 
advanced renal cell (RCC) and hepatocellular carcinomas (HCC), has been demonstrated as the 
first molecular targeted agent with significant therapeutic benefits in advanced hepatocellular 
carcinoma (Wilhelm, et al., 2008; Bahman, et al., 2018). Sorafenib has a unique property 
compared to other anticancer drugs is its ability to induce ferroptosis in different cancer cell lines 
including kidney cancer cells (Caki-1, ACHN), colon cancer cells (HCT116, HT-29), and 
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Further studies have shown that combined administration of Celecoxib; a cyclooxygenase-
2 inhibitor, and Sorafenib decreases production of phospho-AKT and increases apoptosis in HCC, 
thus, inhibiting tumor proliferation (Morisaki, et al., 2013).  
 Moreover, Sorafenib treatment of androgen-independent prostate cancer patients (AIPC) 
and  prostate cancer cell lines (PC3, DU145 and 22Rv1) showed significant clinical effects and 
reduced cell viability by inducing apoptosis respectively  (Ullen, et al., 2010). Sorafenib has 
demonstrated clinical effects in three independent phase II trials in patients with hormone 
refractory and metastatic prostate cancer (Ullen, et al., 2010).  
Furthermore, Sorafenib was shown to inhibit the growth of the colon cancer cell lines 
SW480, HT29 and SW620, at a dose as low as 5µg/ml (Wehler, et.al, 2012). The combination of 
5-Fluorouracil (0.5 mg/ml of 5-FU) and Sorafenib (5µg/ml) revealed additive effects in SW480 
and HT29 cells (Wehler, et.al, 2012).  
Knowing that the cell lines SW480 and SW620 exhibit mutated p53 gene (Lamy, et.al, 
2010), it was stated that despite these mutations, depending on the cellular stress, the p53 protein 
may retain its ability to induce DNA repair mechanisms, apoptosis, and cell cycle arrest (Rochette, 
et.al, 2005). In this study, the effect of Sorafenib on two well-characterized in vitro human 
colorectal cancer cell lines with different p53 status is being investigated.  P53, a tumor suppressor 
gene, is activated in response to stress and can promote the permanent removal of nascent cancer 
cells through the induction of various forms of cell death or senescence, responses that contribute 
to the ability of p53 to limit tumor development (Blagih, Buck & Vousden, 2020). In addition, 
cell-cycle arrest and apoptosis are the most prominent biological outcomes of p53 activation in 
cell culture experiments (Chen, 2016). Many studies showed that the p53 apoptotic function is 
important for preventing tumor development (Blagih, Buck & Vousden, 2020). Therefore, to study 
whether Sorafenib exerted an inhibitory effect in a p53-independent way, we chose the wild type 




Sorafenib was purchased from Santa Cruz Biotechnology, Dallas, TX, USA. Human 
colon cancer cells (HCT116, HCT116P53-/-, SW948 and SW837) were obtained from 
American Type Culture Collection (ATCC), Manassas, VA, USA. Roswell Park Memorial 
Institute media ((RPMI, cat # R7388), Heat inactivated fetal bovine serum (FBS, cat # 
F9665), Phosphate Buffered Saline (10X PBS, cat # D1408), Penicillin-Streptomycin (PEN-
Strep mixture, cat # L0022-100), Trypsin-EDTA 10X solution (cat # T3924), antioxidants N-
acetylcysteine (NAC) (cat # A9165), Catalase (cat # 3515) and Propidium iodide (cat # 
P4170), and 6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxylic acid (Trolox)  were 
purchased from Sigma-Aldrich, USA. 
The Cell Proliferation Kit I for viability assay (MTT, cat # 11 465 007 001) was 
obtained from Roche (Mannheim-Germany). Annexin V-FITC Apoptosis Detection Kit (cat 
# ab14085) was bought from Abcam and p -Nitro Blue Tetrazolium Chloride (NBT, cat # 
6876) was from MP chemicals (CA-USA). 
 
2.2 Preparation of Sorafenib 
Sorafenib was dissolved in dimethyl sulfoxide (DMSO), at varying concentrations 
ranging between 5µM-100µM then aliquoted and stored at -20⁰ C. 
 
2.3 Culture conditions of Colon Cancer Cell Lines 
HCT116, HCT116P53-/-, SW948 and SW837 colon cancer cells (CCC) were cultured 
in media supplemented with 10% fetal calf serum, 0.5% penicillin and streptomycin and 
incubated in humidified 5% CO2 incubator at 37°C. RPMI was the media used for HCT116 
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2.4. Cell Viability 
Cell viability was evaluated using MTT assay and Trypan Blue exclusion test.  
 
2.4.1. MTT assay 
Viable cells were stained by using 3-(4-5 dimethyl thiazol-2yl)-2,5 diphenyl 
tetrazolium bromide (MTT) following the supplier’s instructions. CCC (1×104 
cells/well) were seeded in 96 well plates, then cultured under standard conditions and 
treated with Sorafenib (5 to 75µM) for 24 h. Viability of cells was compared to 
control cells treated with vehicle (DMSO, 0.1%).   MTT reagent (10µl) was then 
added, incubated for 4 h followed by the addition of solubilizing reagent (100μl) and 
incubation overnight. Cell viability was measured by examining the cellular 
reduction of the yellow MTT to the insoluble purple formazan form by the 
metabolically active cells. Absorbance of the developed color was measured using 
the ELISA reader Multiskan EX (Thermo) at 595 nm. Percent viability of treated 
cells was calculated as follows: 
                          % Viability = [Abs (treated cell)/ Abs (control)] ×100 (Katerji, et. al, 2017) 
 
2.4.2.  Trypan blue exclusion assay 
The effect of Sorafenib on the viability of the CCCs was also determined by 
trypan blue exclusion test. Cells (1×105/ml/well) were seeded in 12 well plates, 
treated with Sorafenib (5µM-75µM) for 24 h. They were then trypsinized, collected 
by centrifugation, resuspended in media: trypan blue solution (1ml:10µl) and counted 
using hemocytometer under a light microscope.  
% Viability = [number of treated unstained cells/ total number of stained and 
unstained cells] ×100 (Ballout, et. al, 2020) 
 
2.5. Nitroblue Tetrazolium (NBT) Reduction Assay 
CCCs were seeded in 96 well plates at a density of 1×104/100µl for HCT116 and 
1.2×104 for HCT116P53-/-. Cells were then treated with Sorafenib for 24 h, each at its 
corresponding EC50. The level of reactive oxygen species (ROS) was indirectly determined 
using the nitro-blue tetrazolium (NBT) assay (Muñoz et al., 2000). In short,  freshly 
prepared NBT (1 mg/ml, 100µl) was added to control and Sorafenib treated cells, incubated 
for 1hr, then washed with methanol (100µl/well), then left to dry at room temperature. The 
formed formazan crystals were solubilized by consecutive addition of KOH (2M, 120µl) 
and DMSO (140 μl). Absorbance of the developed blue turquoise color was read at 630 nm 
using Elisa Multiskan EX Reader.  
The % of reduced NBT and % of generated ROS were determined as follows: 
 
%NBT reduction = (Abs of Sorafenib-treated cells /Abs of control) ×100 
% ROS production = 100 - %NBT reduction  
 
The level of ROS generated is inversely proportional to the level of NBT reduced (Al Wafai, 
et. al, 2017). 
 
 
2.6.Effect of Antioxidants on Sorafenib Treated Colon Cells 
The possible protective effect of the antioxidants NAC, Trolox and enzyme catalase 
on viability and ROS production in Sorafenib treated colon cancer cells was assessed. 
Seeding was done as described before in the respective assays. CCC were pretreated for 
2hrs with NAC (5mM), Trolox (100µM), or Catalase (8 Units) followed by Sorafenib 




2.7. Wound Healing Assay  
Wound healing assay was performed to qualitatively determine the effect of 
Sorafenib on cell migration. CCCs were seeded in 6 well plates at density of 20x104 cells 
/well and a scratch wound was made in the monolayer with a sterile pipette tip. Cells were 
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then washed with PBS to remove debris and new media were added. Phase-contrast images 
of the wounded area were taken at 0 and 24 hours. Wound widths were measured at 3 
different points for each wound, and the average rate of wound closure was calculated in 
μm/hr (Karakuş, et al., 2018). 
 
2.8. Apoptosis Analysis 
Annexin-V is a protein that binds the surface phospholipids (PS) in apoptotic cells. 
Annexin-V/propidium iodide double staining was used to measure the percentage of 
apoptotic cells according to the annexinV FITC apoptosis detection kit (ABCAM). HCT116 
and HCT116-P53-/- cells were cultured in 6-well plates at a density of 1×105cells/ml, and 
treated for 24hr with Sorafenib at (EC50). Cells were then trypsinized, washed with PBS, 
re-suspended in Annexin-V-FITC and PI containing binding buffer (20 µl of 1mg/ml), and 
incubated for 5 min at room temperature in the dark. The Annexin-V FITC−/PI− cell 
population was considered normal, whereas the Annexin-V FITC+/PI− and Annexin-V 
FITC+/PI+ were indicative of early and late apoptotic cells respectively. Five thousands 
ungated events were collected for each sample.  Flow cytometry data were plotted and 
analyzed by the fluorescence Guava Easy Ctye8 Flow Cytometer (Millipore/Merck, CA, 
USA).  
 
2.9. Effect of Sorafenib on SW948 and SW837 Cell Lines 
To study the effect of Sorafenib on Colon cancer cells with two different P53 
mutations in Human colorectal adenocarcinoma cell lines, SW948 (G117fs) & SW837 
(R248W) were used. Cells were cultured with DMEM media supplemented with10%FBS 
and 1%PS, seeded in 96-wellplates (1 × 104 cells/well) and 12-well plates (1 × 105 
cells/well) and treated for 24h with the appropriate concentrations of Sorafenib. Viability 
and NBT assay were examined in Sorafenib treated SW948 and SW837 cell lines. 
 
2.10.  Statistical Analysis 
Microsoft Excel independent student t-test  was used to determine the statistical 
significance. P-values ≤ 0.05 were considered significant. For each parameter tested, at least 
three experiments were performed with triplicate determinations in each. Moreover, for 
each parameter, statistical significance relative to the control and inter-categorical 





3.1. Sorafenib Decreases Viability of Human Colon Cancer Cells 
The effect of Sorafenib on the viability of HCT116 and HCT116P53-/- was assessed 
using both MTT and trypan blue exclusion assays (Figures 2A and 2B). A dose dependent 
decrease in cell proliferation was obtained in both assays. 
Using MTT assay, a 50% cell death (EC50) occurred at 50M and at 35µM for 
HCT116 and for HCT116P53-/- respectively (Figure 2A). Trypan blue exclusion assay 
showed that Sorafenib exerted the same effect at lower concentration. The obtained EC50 
were 10µM and 25µM for HCT116 and for HCT116P53-/- respectively (Figure 2B), which 









Fig.2:  A) Effect of varying Sorafenib concentrations on viability of HCT116 and HCT116p53-/-cells using 
MTT assay. B) Effect of varying Sorafenib concentrations on viability of HCT116 and HCT116p53-/- cells 
using Trypan Blue Exclusion Assay. Data presented are the mean ± SEM of 9 determinations from three 
different experiments. Asterisks on bars represent significance relative to the control. (*), (**), and (***) 
correspond to P<0.05, 0.01, and 0.001, respectively. 
 
 
3.2. Sorafenib Induces ROS Production 
Treating HCT116 and HCT116p53-/- with Sorafenib (5 to 50 µM) significantly 
(p<0.05) increased ROS production in a dose dependent manner. A 25.6% to 53% increase 
in ROS production was observed in HCT116 and 9% to 52% in HCT116p53-/- after 24 
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Fig.3: Effect of Sorafenib on ROS Production. Cells were treated with Sorafenib at different 
concentrations for 24-h. Data presented are the mean ± SEM of 9 determinations from three different 
experiments. Asterisks on bars represent statistical significance relative to the control. (*) and (**) 
correspond to P<0.05 and 0.01 respectively. 
 
 
3.3. Effect Of Antioxidants On Viability Of Sorafenib Treated Colon Cancer Cells 
We next examined the possible protective effect of the antioxidants (NAC, Trolox), 
and the catalase enzyme in restoring viability of Sorafenib-treated CCC using MTT assay. 
Pre-treatment for 2hrs with each of the antioxidants Trolox, NAC and the catalase enzyme 
exhibited no significant protective effect as no restoration in viability was observed in both 




Fig.4: Effect of Antioxidants (Trolox, NAC, and Catalase) on viability of Sorafenib treated HCT116 and 
HCT116p53-/- cells using MTT Assay. Colon Cancer cells were pre-incubated for 2h with NAC (5mM), 
Catalase (8U) and Trolox (100µM) prior to Sorafenib treatment at EC50 and incubation for additional 24-
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3.4. Effect of Antioxidants On ROS Production of Sorafenib Treated Colon Cancer 
Cells 
We next examined the effect of the antioxidants (NAC, Trolox) and the catalase 
enzyme on prevention of ROS generation in Sorafenib-treated CCC using NBT assay. Pre-
treatment for 2hrs with each of the antioxidants Trolox, NAC and Catalase exhibited no 




Fig.5: Effect of Antioxidants (Trolox, NAC) and Catalase on NBT reduction of HCT116 and 
HCT116p53-/- using NBT Assay. Colon Cancer cells were pre-incubated for 2h with NAC (5mM), 
Catalase (8U) and Trolox (100µM), prior to Sorafenib treatment at EC50 for 24-h. Data presented are the 
mean ± SEM of 9 determinations from three different experiments. 
 
 
3.5. Sorafenib Induces Apoptosis of Colon Cancer Cells  
 
To investigate whether cell death observed following Sorafenib treatment in the two 
colon cancer cell lines occurs via apoptotic or necrotic mechanisms, cells were stained with 
fluorescin Isothiocyanate (FITC)-conjugated Annexin-V antibody (Annexin V-FITC) and 
PI followed by flow cytometry.  
Following Sorafenib treatment (24hrs) an increase in the percentage of AnnexinV 
and PI stained CCC cells was obtained, compared to control, indicating late apoptosis. As 
shown in Figure 6, the percentage of cells in late apoptosis were 40% and 60% for HCT116 
and HCT116p53-/- respectively, showing 8 fold increase in the wild type HCT116 when 
comparing treated to control, and 4 fold increase in the mutant type HCT116p53-/-. 
Therefore, upon Sorafenib treatment, HCT116 are more sensitive to cell death than 
HCT116p53-/- .  
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Fig. 6: Apoptosis assessment of Sorafenib-treated colon cells. Figure 6A shows representative 
Annexin-V FITC:PI histograms of Sorafenib-treated cells compared to control for HCT116 and 
HCT116p53-/- cells. Alive cells are Annexin V− /PI−, dead cells are Annexin V− /PI+, early 
apoptotic cells are Annexin V+ /PI− and late apoptotic/necrotic cells (Annexin V+ /PI+).  Figure 6B 
shows the data presented as the mean ± SEM of 3 different experiments. Asterisks on bars represent 
significance relative to the control (**), and (***) correspond to P< 0.01, and 0.001, respectively. 
 
 
3.6. Sorafenib Affects Cellular Motility  
 
The effect of Sorafenib on the motility of the colon cancer cells was investigated in a 
2D system using the wound healing assay. Our results show that Sorafenib induced a 
decrease in motility, causing a 2.5 fold decrease in wound closure in HCT116p53-/- cells 
compared to untreated cells (Figure 7). This experiment was also performed on the wild type 









































Fig.7: Sorafenib inhibits cellular motility.  Monolayers of untreated and Sorafenib-treated 
HCT116p53-/- cells grown in plates were wounded.  Pictures of cells were taken at 0 hr (upper 
micrographs) and 24 hrs (Lower micrographs) post wounding at the same frame. Width of single 
wound was measured at 3 distinct points, and average rate of wound closure was calculated in 
μm/h. Data are the mean -/+ SEM from 3 different wound healing experiments. 
 
3.7. Effect of Sorafenib On SW948 And SW837 Cells 
 
Similar viability profile to that of HCT116 and HCT116p53-/- was obtained in the p53 
wild type SW948 and the mutated SW 837 cells treated with Sorafenib. Using MTT assay, a 
50% cell death (EC50) occurred at 35M and 25M for SW948 and SW837 cells, 
respectively (Figure 8A). Trypan blue exclusion assay showed that Sorafenib exerted the 
same effect at lower concentration. The obtained EC50 was 10µM for both cell lines (Figure 
8B). Sorafenib treatment significantly decreased cell ability to reduce NBT in a dose 
dependent manner in SW948 and SW837 cells, 74.6% and 84.0% (p<0.05), respectively at 
EC50 (Figure 8C). These findings indicate a significant increase in ROS level, 25.4% and 
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Fig.8: Effect of Sorafenib treated SW948 and SW837 cells on:(A) viability using MTT assay; (B) 
Trypan blue exclusion test, (C) ROS level using NBT reduction assay The data presented as the 
mean ± SEM of 3 different experiments. Asterisks on bars represent significance relative to the 
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4. DISCUSSION  
Sorafenib, a novel drug used for the treatment of different types of cancer, has so far 
demonstrated its antitumor activity in patients with hepatocellular carcinoma, sarcoma and renal 
cell cancer (RCC) (Strumberg, 2005). This study was undertaken to investigate the in vitro effect 
of Sorafenib on the colon cancer cell lines HCT116 and HCT116P53-/-. 
Our study reports that Sorafenib treatment showed  a concentration dependent decrease in 
viability (trypan blue) with an estimated EC50 of 10 μM for HCT116  and 25 μM for HCT116 
p53-/- which was comparable with other studies reporting toxicity of Sorafenib at 10μM (Inoue 
et. al, 2011). Compared to trypan blue, MTT results were similar in case of HCT116 p53-/- but 
were significantly different with HCT116. Taking into consideration that trypan blue is a 
qualitative assay determining the number of viable cells based on the cell membrane integrity 
(Strober, 2001), the MTT assay measures mitochondrial function by monitoring the effect of 
Sorafenib, on the activity of mitochondrial dehydrogenase. MTT assay measure cellular viability 
through the mitochondrial activity (van Meerloo et al., 2011). Thus, this discordance may be 
attributed to the possible interference of Sorafenib with the MTT assay.  
 Sorafenib was cytotoxic to the two cell lines used and inhibited their growth at 10-25 µM 
(EC50 from Trypan blue exclusion test), which shows that the two cell lines HCT116 and 
HCT116P53-/- were responsive to Sorafenib, but the wild type HCT116 was more sensitive to the 
drug. These concentrations were similar to those obtained on CHLA-90 neuroblastoma cancer 
cells (10µM) obtained by Reynolds et al. (2013) where Sorafenib also showed anti-proliferative 
activity. Another study done by Cervello et al. (2012) showed a substantial dose-dependent 
decrease in cell viability in the two tested cell lines HepG2 and Huh7, where after 24hr of 
treatment with Sorafenib, the IC50 values were 12 μM in HepG2 cells and 11.3μM in Huh7 cells 
(Cervello et al, 2012).  
Previous studies have shown that reactive oxygen species (ROS) play an important role in 
cancer (Prasad, et. al, 2017). Knowing that low levels of ROS could be beneficial, its excessive 
accumulation can induce cancer. One of the main characteristic of cancer cells that differentiate 
them from other normal cells is their ability to produce high levels of ROS and their increased 
dependence on an antioxidant defense system (Prasad, et. al, 2017). Our data shows that Sorafenib 
significantly decreased NBT reduction in the two cell lines HCT116 and HCT116p53-/- treated 
cells indicating an increase in ROS level. Furthermore, our results did not show a restoration of 
viability when pre-treated with antioxidants, and there was no significant change in ROS 
generation upon the pre-treatment of the two cell lines HCT116 and HCT116P53-/- with NAC and 
Trolox. However, Wan et al. showed that ROS generation was markedly abrogated when colon 
cancer cells HCT116 were pretreated with NAC, then treated with a combination Sorafenib and 
tetrandrine (Wan, et al., 2013). Glutathione system is considered the cells' first line defense 
against extracellular ROS. In our study NAC that is not only considered as a ROS scavenger, but 
also one of precursors of glutathione synthesis (Li, et. al, 2016) was not able to rescue the HCT116 
cells implying that cell death is not mediated through ROS production and rather ROS production 
is a consequence leading to cell death.  
An increase in ROS production leads to genotoxic damage, which may lead to apoptosis 
or necrosis. Apoptosis is programmed cell death type I. Apoptosis plays an important role in 
maintaining cellular function in various tissues and organs (Tower., 2015). In our experiment, we 
evaluated apoptosis using Annexin V and PI double staining followed by flow cytometry. Our 
results indicate that Sorafenib significantly induces apoptosis in HCT116 and HCT116P53-/- cells 
showing 8 fold increase in the wild type HCT116 when comparing treated to control, and 4 fold 
increase in the mutant type HCT116p53-/-, indicating that both cell lines have the same response 
to Sorafenib, with higher sensitivity seen in HCT116. Compared to other studies (Zhoa et al., 
2013), Sorafenib induced apoptosis in HCC cell lines, specifically Huh7 and LH86 cells after 
24hrs. Therefore, in  this  study,  we hypothesized and presented partial evidence that  p53  status  
in  colon cancer  cells  may predict  their  sensitivity  toward Sorafenib. P53, the tumor-suppressor 
protein, is a master regulator of apoptosis, in response to cellular stress (Farnebo  et  al.,  2010).  
Previous studies showed the role of   p53   in   the   differential   sensitivity   to   a combined 
treatment of Sorafenib and OSU-2S on HepG2 cells and Hep3B cells, by abrogating the 
sensitivity of HepG2 cell by p53 knockdown and rendering Hep3B cells much more sensitive by 
p53 overexpression (Omar et. al, 2016). To test whether the effect of Sorafenib is specific to 
HCT116 and HCT116p53 -/- cells only or not, we determined its effect on two additional cell lines, 
11
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the SW948 and SW837cells. In our study, we showed that HCT116 was more sensitive to 
Sorafenib than HCT116p53-/- with an EC50 of 10 µM and 25µM, respectively.  Sorafenib treated 
SW948 and SW837 cells had similar effects to those of HCT116 and HCT116p53 -/-cells in terms 
of viability (EC50 = 10µM), and ROS generation implying the involvement of p53 in the 
sensitivity toward Sorafenib.  
Our findings further revealed that Sorafenib inhibited the 2D cell motility of HCT116p53 
-/- colon cancer cells. This property has been previously reported in other cancer models including 
ovarian cancer (Park, et. al, 2017) and hepatocellular carcinoma (HCC) (Yoshida, et. al, 2017). 
For instance, Sorafenib was shown to inhibit the migratory activity of EGF-treated SK-OV-3 and 
Caov-3 cells (Park, et. al, 2017). Sorafenib was also shown to suppress the cell motility of HLF 
cells (Yoshida, et. al, 2017). This is thus the first evidence of Sorafenib’s antimigratory effects in 
CCCs in 2D, in vitro. In addition, while performing wound healing experiment, HCT116 did not 
adhere to culture plates after Sorafenib treatment, and this was comparable to a previous study 
that supports our findings, where HCT116 cells did not adhere to culture plates pre-coated with 
fibronectin after lactose and water soluble papaya pectin (3PP) treatments (do Prado, et. al, 2017). 
Hence, the differences in cell migration in both cell lines, wild type and mutant type could be 
related to the microenvironment that likely plays a crucial role in tumor growth and metastasis.  
Taken together, these findings confirm that Sorafenib induces apoptosis and inhibit 
proliferation in ROS and P53 independent manner. 
 
5. CONCLUSION 
In summary, Sorafenib, independently from p53, exerted an anti-cancer effect on colon 
cancer by an increase in ROS production and inducing apoptosis. Furthermore, our results add to 
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